Publications by authors named "Shanshan Weng"

Article Synopsis
  • Extramammary Paget's disease (EMPD) is a rare skin cancer with an unclear cause and potential to spread, where surgery is the main treatment but more effective therapies are needed.
  • In a study analyzing 815 EMPD patients, factors like older age, metastasis, and radiotherapy were linked to worse outcomes, while chemotherapy seemed to have a negative impact on patient prognosis.
  • The research indicated that EMPD tissues had more immune-related activity, particularly in patients with low ERBB2 expression, suggesting that these patients might benefit from immunotherapy focusing on B cells.
View Article and Find Full Text PDF

The first-line therapy pattern transition of metastatic HER2-positive gastric cancer is shifting. The KEYNOTE-811 study demonstrated that the addition of immunotherapy to the standard treatment of HER2-targeted therapy and chemotherapy showed good results in terms of PFS, especially in subgroup patients with PD-L1 CPS≥1. In the future, the first-line therapy pattern of metastatic HER2-positive gastric cancer will be radically changed based on ongoing randomized controlled clinical trials.

View Article and Find Full Text PDF

Background: The death burden attributable to modifiable risk factors is key to colorectal cancer (CRC) prevention. This study aimed to assess the prevalence and regional distribution of attributable CRC death burden worldwide from 1990 to 2019.

Methods: We extracted data from the Global Burden of Disease Study in 2019 and assessed the mortality, age-standardized death rate (ASDR), population attributable fractions, and time trend in CRC attributable to risk factors by geography, socio-demographic index (SDI) quintile, age, and sex.

View Article and Find Full Text PDF

Colorectal cancer (CRC) is one of the most common malignancies, and at the initial visit, most patients are diagnosed with metastatic CRC (mCRC). However, immunotherapy is only and highly effective in a very small proportion of patients with mCRC having mismatch repair defect (dMMR)/high microsatellite instability, and the majority of the patients with mCRC having mismatch repair proficient (pMMR)/microsatellite stability (MSS) cannot benefit from it. At present, many clinical studies of immunotherapy combined with tyrosine kinase inhibitors (TKIs) are trying to regulate the immune microenvironment of pMMR/MSS mCRC, transforming a "cold tumor" into a "hot tumor," which has not only surprising effects but also certain limitations, i.

View Article and Find Full Text PDF

Recent years have witnessed increasing studies on the effect of epigenetic silencing of genes in the progression of chronic lymphocytic leukemia (CLL). This study investigates whether the nucleotide binding oligomerization domain containing 2 (NOD2) participates in the cell apoptosis and drug resistance of CLL cells. Cells were treated with adriamycin (ADR), etoposide, aclacinomycin and daunorubicin.

View Article and Find Full Text PDF

Background: Microsatellite stable (MSS) and RAS-mutant metastatic colorectal cancer (mCRC) patients are characterized by an immunosuppressive microenvironment and a low response rate to immunotherapy. Chemotherapy and anti-angiogenesis therapy have been reported to potentially promote immunotherapy response. This study aims to assess the preliminary anti-tumor activity and safety of sintilimab plus bevacizumab, oxaliplatin and capecitabine as a treatment option for patients with RAS-mutant MSS mCRC.

View Article and Find Full Text PDF

Background: Rat sarcoma viral oncogene homolog (RAS) gene mutation is a common molecular event in colorectal cancer (CRC). The prognosis of mCRC (metastatic colorectal cancer) patients with RAS mutation is poor and capecitabine and oxaliplatin (CapeOx) plus bevacizumab has shown to be one of the standard therapeutic regimens as first line for these patients with objective response rate (ORR) of ~ 50% and median progression-free survival (mPFS) of 8-9 months. Immunotherapy, especially anti-programmed death 1 (PD-1) monoclonal antibody has demonstrated ground-breaking results in deficient mismatch repair (dMMR) / microsatellite instability-high (MSI-H) mCRC patients.

View Article and Find Full Text PDF

has become one of the most challenging pathogens in many countries with limited treatment options available. Cefiderocol, a novel siderophore-conjugated cephalosporin, shows potent activity against , including isolates resistant to carbapenems. To date, few reports on the mechanisms of cefiderocol resistance are available.

View Article and Find Full Text PDF

Background: Occupational-related cancers are a substantial global health issue. The largest proportion of occupational-related cancers is tracheal, bronchus, and lung (TBL) cancer. This study aimed to explore the geographical and temporal trends in occupational carcinogens related to TBL cancer.

View Article and Find Full Text PDF

The study was designed to explore the role of PSMA3-AS1 in initiation and progression of acute myeloid leukemia (AML) and investigate its action mechanism. Expression of PSMA3-AS1, miR-20a-5p and ATG16L1 both and was measured by qRT-PCR. The expression of protein was detected by western blot assay.

View Article and Find Full Text PDF

Internal tandem duplication (ITD) is the most common type of FLT3 mutation (FLT3-ITD), accounting for about 25% of AML patients. The expression of DANCR in FLT3-ITD AML had not been paid attention to, and whether its regulatory relationship with IGF2BP2 can affect the progression of FLT3-ITD AML was unclear. Our study sought to verify the biological role of IGF2BP2 as an m6A reading protein in FLT3-ITD AML.

View Article and Find Full Text PDF

Objective: To develop a scoring system based on clinical and imaging features to distinguish complicated appendicitis (CA) from uncomplicated appendicitis (UCA) during pregnancy.

Method: This was a retrospective case-control study. Patients diagnosed with acute appendicitis during pregnancy were included, and they were divided into a CA group and a UCA group based on the intraoperative findings and the biopsy results.

View Article and Find Full Text PDF
Article Synopsis
  • Ensartinib is a second-generation tyrosine kinase inhibitor tested in a phase I clinical trial for patients with advanced ALK-rearranged non-small cell lung cancer, focusing on its safety, dosage tolerability, and anti-tumor activity.
  • The trial involved 48 patients, primarily those who had never received prior ALK treatments, with a maximum tolerated dose of 225 mg per day identified; common side effects included rash and elevated liver enzymes.
  • The treatment showed promising results, with a 64.6% objective response rate and a median progression-free survival of 16.79 months, indicating potential effectiveness against this type of cancer.
View Article and Find Full Text PDF

GEC is one of the most common cancers and has become a significant health burden worldwide. HER-2 is a proto-oncogene, amplified or overexpressed in different tumors, and associated with a worse prognosis. Trastuzumab plus chemotherapy is the current standard treatment for advanced HER-2 positive GEC.

View Article and Find Full Text PDF

Lung adenocarcinoma (LUAD) remains one of the leading causes of cancer-related death. Although immunotherapy has been shown to improve survival in LUAD patients, only a select group of LUAD patients could benefit from it. The correlation between ferroptosis and the tumor immune environment requires further investigation in the setting of LUAD.

View Article and Find Full Text PDF

Multiple primary malignancies (MPMs) are defined as the coexistence of at least two unrelated primary malignancies in a single patient, with the tumors differing in their histology. MPMs in the same patient, when present within 6 months of the primary tumor diagnosis, are considered a synchronous occurrence. In this case report, we describe a 61-year-old man who presented with three distinct tumors concurrently in 2021: noninvasive urothelial carcinoma of the bladder, diffuse large B-cell lymphoma, and squamous cell carcinoma of the lung.

View Article and Find Full Text PDF

REV1 is a member of the translesion synthesis DNA polymerase Y family. It is an essential player in a variety of DNA replication activities, and perform major roles in the production of both spontaneous and DNA damage-induced mutations. This study aimed to explore the role of REV1 as a prognostic biomarker and its potential function regulating the sensitivity of anti-tumor drugs in various cancers.

View Article and Find Full Text PDF

Hairy and enhancer of split homolog-1 (HES1), regulated by the Notch, has been reported to play important roles in the immune response and cancers, such as leukemia. In this study, we aim to explore the effect of HES1-mediated Notch1 signaling pathway in chronic lymphocytic leukemia (CLL). Reverse transcription quantitative polymerase chain reaction and Western blot assay were conducted to determine the expression of HES1, Notch1, and PTEN in B lymphocytes of peripheral blood samples of 60 CLL patients.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Shanshan Weng"

  • - Shanshan Weng's research predominantly focuses on the intersection of immunotherapy and cancer treatment, particularly in colorectal cancer and extramammary Paget's disease, exploring novel therapeutic strategies and understanding resistance mechanisms. - Recent studies highlight the significance of immunotherapy in managing conditions like HER2-positive gastric cancer and metastatic colorectal cancer, advocating for paradigm shifts in first-line treatment protocols based on emerging clinical trial results. - Weng's contributions also extend to the epidemiological analysis of cancer burdens, emphasizing the impact of modifiable risk factors on colorectal cancer mortality and the need for personalized medicine in clinical practice to improve patient outcomes.